Refractory Thrombotic Thrombocytopenic Purpura: A Case Report
Published: March 1, 2018 | DOI: https://doi.org/10.7860/JCDR/2018/28444.11237
Mohammed Shafi Abdulsalam, Venkateshwaran Radhakrishnan, Prabu Pandurangan
1. Former Registrar, Department of Haematology, Apollo Hospital,Chennai, Tamil Nadu, India.
2. Postgraduate Student, Department of General Medicine, Apollo Hospital, Chennai, Tamil Nadu, India.
3. Senior Consultant Haematologist, Department of Haematology, Apollo Hospital, Chennai, Tamil Nadu, India.
Correspondence Address :
Dr. Prabu Pandurangan,
Greams Road, Apollo Hospital, Chennai-600001, Tamil Nadu, India.
E-mail: drprabu.p@gmail.com
Abstract
Thrombotic thrombocytopenic purpura is a thrombotic microangiopathy. Clinical manifestations occur due to decreased perfusion to the internal organs. Usually it responds to pulse steroids and plasma exchange. Various therapies are available for refractory cases which respond to N-Acetyl cysteine, cyclosporin, rituximab, bortezomib and caplacizumab. We report a case of refractory Thrombotic Thrombocytopenic Purpura (TTP) in a 29-years-old female showed improvement with the use of rituximab (anti-CD 20 monoclonal antibody), who presented with history of fever and one episode of seizure.
Keywords
N-Acetyl cysteine, Rituximab, Splenectomy